Instil Bio, Inc. (TIL)

Instil Bio's stock price has significantly declined over the past six months. As of March 20, 2026, the share price was $8.55, a 56.18% decrease from March 24, 2025. The discontinuation of AXN-2510's clinical development and the termination of the agreement with ImmuneOnco Biopharmaceuticals led to a strategic shift towards external innovation. The company reported its fourth quarter and full year 2025 financial results in March 2026.

Instil Bio, Inc. does not typically experience demand seasonality. The demand for its products and services is driven by the progression of its pipeline, regulatory milestones, and the unmet medical needs in oncology, rather than seasonal consumer patterns.

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer, operating within the Biotechnology industry. The company's pipeline centers around autologous tumor infiltrating lymphocyte (TIL) therapies, with ITIL-306 as a key product candidate targeting folate receptor alpha (Fra) expressed on solid tumors. The development of AXN-2510/IMM2510, a bispecific antibody, was discontinued in January 2026.

Instil Bio, Inc. is headquartered in Dallas, Texas, with research and cell therapy manufacturing facilities in Los Angeles, California, and Manchester, UK. Clinical trials for AXN-2510/IMM2510 included a Phase 1 trial in China.

Instil Bio's brand reputation has faced challenges over the past year. The company has received a "Reduce" consensus rating from analysts. The discontinuation of AXN-2510 and the disclosure of substantial doubt about its ability to continue as a going concern have negatively impacted its standing. The stock has underperformed both the US Biotechs industry and the broader US Market.

Institutional investors hold a significant portion of Instil Bio's stock, with 48 owners holding 4,476,672 shares. Major institutional owners include Curative Ventures V LLC, BML Capital Management, LLC, CPMG Inc, Vivo Capital, LLC, Millennium Management Llc, Siren, L.L.C., Vanguard Group Inc, Morgan Stanley, Renaissance Technologies Llc, and Dimensional Fund Advisors Lp. Insiders hold approximately 94.49% of the stock, with Curative Ventures V LLC being the largest individual shareholder.